Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants such as mycophenolate mofetil and azathioprine. Since the 2017 launch of eculizumab (Soliris, biosimilars), new therapies, with differentiated mechanisms of action, have begun reshaping MG care. FDA approvals include efgartigimod alfa (Vyvgart) in 2021 and its subcutaneous form (Vyvgart Hytrulo) in 2023, ravulizumab (Ultomiris) in 2022, rozanolixizumab (Rystiggo) and zilucoplan (Zilbrysq) in 2023, and nipocalimab (Imaavy) in 2025. In the context of this evolving landscape, this report uses real-world claims data to illustrate prescribing trends and support emerging drug developers in identifying market opportunities.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MG patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MG patients?
• How have Imaavy, Soliris, Vyvgart, Ultomiris, and Rystiggo been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of MG patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of MG patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Geography: United States

Key drugs covered: Imaavy, Soliris, Vyvgart, Ultomiris, Rystiggo

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.